Hepatic Safety of Ketamine and Esketamine for TRD Patients

Ketamine and Esketamine Show Hepatic Safety in TRD

A recent study published in July 2026 provides evidence that ketamine and esketamine are safe for the liver when used in therapeutic settings for treatment-resistant depression (TRD). Conducted at the Mayo Clinic Ketamine Clinic, the study followed 104 adults with TRD who received intravenous (IV) ketamine or intranasal (IN) esketamine between 2017 and 2024. The findings revealed no clinically significant changes in liver enzyme levels, suggesting that routine hepatic monitoring may not be necessary for asymptomatic patients.

Mechanism and Context of the Study

The study aimed to address concerns about the hepatic safety of ketamine and esketamine, particularly given the known risks associated with chronic recreational use of ketamine, such as cholestasis and cholangiopathy. By focusing on subanesthetic doses used for depression treatment, the researchers sought to provide a clearer understanding of the potential liver-related risks in a clinical setting. The study utilized generalized linear-mixed models to analyze liver enzyme trajectories and found that only 5.9% of patients experienced significant enzyme elevations, all of which were attributed to factors other than the treatment itself.

Policy and Research Implications

The study's findings have important implications for clinical practice and policy. By indicating that routine liver monitoring may not be necessary for asymptomatic patients, the research could help reduce barriers to access and streamline treatment protocols for TRD. This could lead to broader adoption of ketamine and esketamine therapies, particularly in settings where resources for extensive monitoring are limited. However, the study also highlights the need for further research to confirm these results in larger and more diverse populations.

Risks and Unknowns

Despite the positive findings, there are still risks and unknowns that need to be addressed. The study's cohort was relatively small, and the follow-up period was limited to three months post-treatment. Additionally, the study did not include patients with pre-existing liver conditions, which could affect the generalizability of the results. As such, larger-scale, prospective studies are necessary to fully understand the long-term hepatic safety of ketamine and esketamine in diverse patient populations.

Looking Forward

As the use of ketamine and esketamine for TRD continues to grow, ongoing research will be crucial in ensuring their safe and effective implementation. Future studies should aim to include larger cohorts and longer follow-up periods to provide more comprehensive data on the hepatic safety of these treatments. Additionally, exploring the effects of ketamine and esketamine in patients with varying degrees of liver health could offer valuable insights into their broader applicability.